Baptist Memorial Health Care/Mid South NCORP Minority Underserved Consortium
浸信会纪念医疗保健/中南 NCORP 服务不足的少数民族联盟
基本信息
- 批准号:10221621
- 负责人:
- 金额:$ 144.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AchievementActive SitesAmbulatory CareAmerican College of Radiology Imaging NetworkArkansasBaptist ChurchBreastCancer ControlCancer PatientCancer Therapy Evaluation ProgramCaringCatchment AreaChestClinicClinical OncologyClinical TrialsCommunitiesCommunity HealthcareCountyDataDevelopmentDiseaseEastern Cooperative Oncology GroupElectronic Health RecordEnrollmentFoundationsFundingGenitourinary systemGoalsGynecologic OncologyHealthHealth Service AreaHealthcareHealthcare SystemsHeelHematologyHospitalsIndigentIndividualInfrastructureInfusion proceduresInstitutionLinkMalignant NeoplasmsMalignant neoplasm of thoraxMedicaidMinority GroupsMissionMississippiOncologistOncologyOutpatientsPathologyPatient RecruitmentsPatientsPopulationPreventionPrivate PracticeProtocols documentationProviderPublic HealthQuality of CareRadiationRecruitment ActivityResearchResearch InfrastructureResearch PersonnelResourcesRural PopulationScienceSiteSouthwest Oncology GroupSystemTennesseeUnderinsuredUnderserved PopulationUninsuredanticancer researchauthoritybasecancer carecancer preventioncare deliveryforestgastrointestinalhealth disparityimprovedinpatient servicemembermultidisciplinaryparticipant enrollmentprogramsracial minorityrural areasocial health determinantssocioeconomicssuccessunderserved minority
项目摘要
The Baptist Memorial Health Care/Mid-South Minority Underserved NCORP is part of Baptist Memorial
Healthcare Corporation (BMHCC), a non-for-profit faith-based healthcare system with 22 hospitals, 21
outpatient oncology clinics, 8 radiation facilities, and 19 outpatient infusion centers, providing care for
approximately 8000 new cancer patients each year. BMHCC’s service area covers 111 counties, 4.3 million
people. This is 44% of the 252 counties and parishes in the Delta Regional Authority, congressionally
acknowledged as the most indigent population in the US. BMHCC provides 25% of cancer care in this racially,
socioeconomically and culturally diverse region, which has some of the highest volumes of cancer and the
most fragile public health infrastructure in the US. Before our NCORP, these patients had no access to clinical
trials. In the 4 years since our NCORP began in August 2014, more than 90 patients per year have been
enrolled into trials, including 168 patients in 2017/18; 39% of our enrolled patients are racial minorities, 17%
reside in rural areas, 13% are uninsured, 21% have Medicaid. Members of our NCORP serve on multiple
NCORP taskforces and NCI Steering Committees, including the Cancer Prevention Steering Committee. We
have used our unique expertise in establishing Multidisciplinary Care Delivery programs in Breast, Thoracic,
Gastrointestinal and Hematologic Oncology to develop Disease-Specific Research Groups that link our
NCORP research closely to our clinical oncology care programs. This strategy has accelerated our progress in
the past 2 years. Our system-wide implementation of the Electronic Health Record system, EPIC, has
enhanced our research ability, especially in Cancer Care Delivery Research. For the new funding cycle, we
propose to expand our NCORP research infrastructure across the full extent of BMHCC, with special emphasis
on increasing patient recruitment across the state of Mississippi. Using Implementation and Team Science
principles and a data-driven approach, our overarching goal is to increase the proportion of BMHCC oncology
patients who participate in clinical trials from <3% in 2018 to 10% by 2025. With almost 8000 annual new
cancer cases, this would significantly exceed the minimum requirements of the NCORP, to the benefit of our
patients, communities and healthcare system, because we believe that ‘the best treatment is a clinical trial.’
Our specific aims are to increase the: 1.) number of active sites from 5 to 16 by 2025, by expanding to all our
Mississippi institutions; 2.) proportion of oncology-related providers accruing patients to >90%; 3.) clinical trials
activity in urogenital and gynecologic oncology; 4.) average annual patient-enrollment into NCORP trials from
90 to >250. Achieving our goal will help achieve the NCI’s mission of improving the health of this key US
population demographic by narrowing a major recognized health disparity: poor access of the large indigent,
racial minority and rural populations within the Mississippi Delta region to high quality oncologic care.
浸信会纪念医疗保健/中南少数民族服务不足NCORP是浸信会纪念的一部分
医疗保健公司(BMHCC),一个非营利性的基于信仰的医疗保健系统,拥有22家医院,21
门诊肿瘤诊所,8个放射设施和19个门诊输液中心,为
每年约有8000名新癌症患者。BMHCC的服务区域覆盖111个县、430万人
人这是三角洲地区管理局252个县和教区的44%,
被认为是美国最贫困的人口。BMHCC在这个种族中提供了25%的癌症治疗,
社会经济和文化多样的地区,其中有一些最高数量的癌症和
美国最脆弱的公共卫生基础设施。在我们的NCORP之前,这些患者无法获得临床
审判自2014年8月我们的NCORP开始以来的4年中,每年有90多名患者
2017/18年入组试验,包括168例患者; 39%的入组患者是少数民族,17%是少数民族。
居住在农村地区,13%没有保险,21%有医疗补助。我们的NCORP成员服务于多个
NCORP工作组和NCI指导委员会,包括癌症预防指导委员会。我们
利用我们独特的专业知识,在乳腺,胸部,
胃肠道和血液肿瘤学发展疾病特异性研究小组,将我们的
NCORP的研究与我们的临床肿瘤护理计划密切相关。这一战略加快了我们在以下方面的进展:
过去两年。我们在全系统范围内实施的电子健康记录系统EPIC
增强了我们的研究能力,特别是在癌症护理提供研究方面。在新的融资周期中,我们
我建议在整个BMHCC范围内扩大我们的NCORP研究基础设施,特别强调
增加密西西比州的病人招募。使用实施和团队科学
原则和数据驱动的方法,我们的总体目标是增加BMHCC肿瘤学的比例
参与临床试验的患者从2018年的<3%增加到2025年的10%。每年新增近8000个
癌症病例,这将大大超过NCORP的最低要求,对我们的利益
患者、社区和医疗保健系统,因为我们相信“最好的治疗方法是临床试验”。
我们的具体目标是增加:1。到2025年,通过扩展到我们所有的
密西西比机构; 2.)肿瘤学相关提供者的比例累积患者至>90%; 3.)临床试验
泌尿生殖和妇科肿瘤学活动; 4.)NCORP试验的平均年患者入组人数
90到250。实现我们的目标将有助于实现NCI的使命,即改善美国这一关键人口的健康状况。
通过缩小公认的一个重大健康差距,
少数民族和农村人口在密西西比三角洲地区的高质量的肿瘤治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Raymond U Osarogiagbon其他文献
Raymond U Osarogiagbon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Raymond U Osarogiagbon', 18)}}的其他基金
Baptist Health System/Mid South NCORP Minority Underserved Consortium
浸信会医疗系统/中南 NCORP 服务不足的少数民族联盟
- 批准号:
9124599 - 财政年份:2014
- 资助金额:
$ 144.94万 - 项目类别:
Baptist Health System/Mid South NCORP Minority Underserved Consortium
浸信会医疗系统/中南 NCORP 服务不足的少数民族联盟
- 批准号:
8901107 - 财政年份:2014
- 资助金额:
$ 144.94万 - 项目类别:
Baptist Memorial Health Care/Mid South NCORP Minority Underserved Consortium
浸信会纪念医疗保健/中南 NCORP 服务不足的少数民族联盟
- 批准号:
10670312 - 财政年份:2014
- 资助金额:
$ 144.94万 - 项目类别:
Baptist Memorial Health Care/Mid South NCORP Minority Underserved Consortium
浸信会纪念医疗保健/中南 NCORP 服务不足的少数民族联盟
- 批准号:
10453639 - 财政年份:2014
- 资助金额:
$ 144.94万 - 项目类别:
Baptist Health System/Mid South NCORP Minority Underserved Consortium
浸信会医疗系统/中南 NCORP 服务不足的少数民族联盟
- 批准号:
9322853 - 财政年份:2014
- 资助金额:
$ 144.94万 - 项目类别:
Improving pathologic nodal staging of resected lung cancer
改善切除肺癌的病理淋巴结分期
- 批准号:
10456918 - 财政年份:2013
- 资助金额:
$ 144.94万 - 项目类别:
Dissemination and implementation of a corrective intervention to improve mediasti
传播和实施纠正干预措施以改善纵隔
- 批准号:
9081558 - 财政年份:2013
- 资助金额:
$ 144.94万 - 项目类别:
Dissemination and implementation of a corrective intervention to improve mediasti
传播和实施纠正干预措施以改善纵隔
- 批准号:
9442358 - 财政年份:2013
- 资助金额:
$ 144.94万 - 项目类别:
Improving pathologic nodal staging of resected lung cancer
改善切除肺癌的病理淋巴结分期
- 批准号:
10214552 - 财政年份:2013
- 资助金额:
$ 144.94万 - 项目类别:
Dissemination and implementation of a corrective intervention to improve mediasti
传播和实施纠正干预措施以改善纵隔
- 批准号:
8830343 - 财政年份:2013
- 资助金额:
$ 144.94万 - 项目类别:
相似海外基金
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334970 - 财政年份:2024
- 资助金额:
$ 144.94万 - 项目类别:
Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
- 批准号:
2400195 - 财政年份:2024
- 资助金额:
$ 144.94万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334969 - 财政年份:2024
- 资助金额:
$ 144.94万 - 项目类别:
Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
- 批准号:
23K04919 - 财政年份:2023
- 资助金额:
$ 144.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
- 批准号:
22KJ2957 - 财政年份:2023
- 资助金额:
$ 144.94万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
- 批准号:
23K04494 - 财政年份:2023
- 资助金额:
$ 144.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
- 批准号:
23K13831 - 财政年份:2023
- 资助金额:
$ 144.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
- 批准号:
2238379 - 财政年份:2023
- 资助金额:
$ 144.94万 - 项目类别:
Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
- 批准号:
2154399 - 财政年份:2022
- 资助金额:
$ 144.94万 - 项目类别:
Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
- 批准号:
RGPIN-2019-06633 - 财政年份:2022
- 资助金额:
$ 144.94万 - 项目类别:
Discovery Grants Program - Individual